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1. Introduction 
Thanks to the intense studies on genes that mediate cancer 
progression and therapeutic resistance, many gene targets that 
regulate apoptosis, proliferation and cell signaling have been 
identified. Multiple cumulative genetic and/or epigenetic changes 
are needed to cause cancer. Molecules that can inhibit expression 
of such genes are powerful tools in cancer research.1  In this 
sense, methodologies focused on sequence-specific gene 
suppression strategies involving antisense oligonucleotides and 
ribozymes or else involving gene silencing using RNA 
interference (RNAi) have been developed.2 However, their 
adaptation as broadly applicable functional genomic and 
therapeutic tools has proven difficult because of problems 
regarding stability and poor efficiency of delivery.  
Many experiments have shown that targeting a single gene can 
inhibit the growth and proliferation of tumor cells.3 However, 
interference targeting a single gene has limitations in the 
prevention and treatment of cancer. It is known that 
tumorigenesis results from multiple gene mutation so that 
therapies targeting multiple genes may have better effects on 
malignant tumors. 
In most solid tumors, angiogenesis is an important process for 
tumor growth and metastasis.4 Many different mediators are 
involved in this process, including VEGF, which has been shown 
to play a critical role in pathological angiogenesis.5 VEGF levels 
in serum are tightly associated to a more aggressive disease state 
and may serve as a marker to evaluate diagnosis. Blocking VEGF 
expression can inhibit tumor growth and prevent metastasis.6 
Most cancer cells also exhibit telomerase activity. The latter 
maintains the length of the telomeres, thus preserving genomic 
stability.7 Telomerase is a ribonucleoprotein composed of two 
main subunits: the human telomerase RNA (hTR) and the human 
telomerase protein (hTERT). Many studies have demonstrated 
that interference of hTERT gene expression can efficiently inhibit 
the growth and tumorigenicity of cancer cells.8 hTERT gene is a 
rate-limiting factor in telomerase synthesis and activity. 
The c-myc gene is amplified in various human cancers, 
including lung carcinoma,9 breast carcinoma10 and colon 
carcinoma.11 The c-myc protein is a transcriptional factor with an 
important role in cell proliferation, differentiation, invasion and 
adhesion of tumor cells.12 It is also involved in the activation of 
hTERT gene transcription. 
The VEGF, hTERT and c-Myc genes therefore may be good 
targets for the development of a new drug with better therapeutic 
effect on malignant tumor.13 
Molecules containing biaryl moieties are relatively common 
within natural products. For their preparation, Nature has 
developed an ample array of biosynthetic strategies.14 A number 
of these biaryl natural products belong to the biogenetic class of 
lignans.15 Two of these, honokiol and magnolol (Figure 1), have 
aroused a great degree of interest because of their various 
pharmacological properties. These products and many derivatives 
thereof, both of natural and synthetic origin, have been reported 
to display antioxidative, anti-inflammatory, anti-tumor, anti-
diabetic, anti-microbial, anti-neurodegenerative, anti-depressant, 
pain control, gastrointestinal, cardiovascular and liver protective 
properties, among others.16,17 
 
 
Figure 1. Structure of honokiol and  magnolol. 
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During the last years, we have been investigating a range of 
analogs of natural products18 for their cytotoxicity and potential 
value in anticancer therapy.19 The latter feature may be related to 
the ability of the compounds to disrupt microtubule dynamics,20 
to inhibit the angiogenesis process21 or to perturb the activation 
of telomerase22 among other alternative mechanisms. Since the 
natural biphenyl derivatives honokiol and magnolol display 
valuable anticancer activity, we decided to prepare a number of 
synthetic biphenyl derivatives (structures depicted in Figure 2), 
and to investigate their behavior in each of the aforementioned 
three types of biological activities. Small molecules have always 
aroused interest in cancer therapy23 so that most of our synthetic 
biphenyl derivatives can be viewed as simplified analogs of 
honokiol and magnolol, where the two allyl residues have been 
removed and one or both OH groups have been replaced by OMe 
or NH2 groups. Even with this structural simplification, the 
retained biphenyl moiety can be still considered a privileged 
structure24 that may prove useful in the development of lead 
compounds. 
  
2. Chemical results 
The preparation of biphenyl derivatives can be performed by 
means of a plethora of methods.25,26 Among them, the Suzuki 
coupling27 has become the method of choice in a high number of 
cases and, indeed, this is the method we have used here for the 
preparation of compounds 1-47. Our syntheses rely on the 
coupling of commercial phenylboronic acids with commercial 
brominated phenols, anilines or anisols under palladium 
catalysis. Four experimental conditions were applied as detailed 
below in Scheme 1. The majority of the compounds was 
synthesized by using conditions A.28 Some compounds, however, 
were reluctant to preparation under conditions A, in which 
PdCl2(dppf)·CH2Cl2 was employed as the catalyst. In these cases, 
Pd(OAc)2 was used as catalyst under several conditions (heating 
at 35°C, as in the synthesis of 9,29 heating at 70ºC, as in the 
synthesis of 11, 20 and 26,29 and heating under microwave 
irradiation30 used in the preparation of amino hydroxyl biphenyls 
14, 17 and 19). For experimental details see Material and 
Methods section. 
3. Biological results 
3.1. Inhibition of cell proliferation 
Cytotoxic of compounds 1-47 was measured by means of their 
IC50 values towards the tumoral cell lines HT-29 and MCF-7 and 
towards the non-tumoral cell line HEK-293. We have also 
evaluated the therapeutic safety margin of each compound as 
expressed by means of the and coefficients. These are 
obtained by dividing the IC50 value of each compound for the non 
tumoral HEK-293 line by those for the HT-29 () and the MCF-7 
() tumoral cell line, respectively (see footnote in Table 1). The 
higher the value of either coefficient, the higher the therapeutic 
safety margin for the corresponding compound. 
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Figure 2. Structures of biphenyl derivatives  investigated in this study. 
 
 
Scheme 1. Synthesis of biphenyl derivatives 1-47. Reagents and conditions: 
A: PdCl2(dppf)·CH2Cl2, 2M Na2CO3, DME, reflux, 15-18 h. B: Pd(OAc)2, 
Na2CO3, ethanol/water (1:1), MW, 150ºC, 1h. C: Pd(OAc)2, Na2CO3, 
ethanol/water (1:1), 70ºC, 4h. D: Pd(OAc)2, Na2CO3, acetone/water (1:1), 
35ºC, 4h. Acronyms: DME = 1,2-dimethoxyethane, dppf = 1,1´-
bis(diphenylphosphino)ferrocene. 
The observed IC50 values are in the low to medium 
micromolar range. In general terms, these biphenyl derivatives 
were more cytotoxic towards the HT-29 line than towards the 
MCF-7 line. Indeed, only compounds 2 and 5 were more 
cytotoxic than honokiol towards the latter cell line. In contrast, 
compounds 3, 4, 8, 9, 15, 20, 26, 30, 40, 46 and 47 exhibited 
lower IC50 values than honokiol on the HT-29 line. Furthermore, 
these compounds also exhibited a markedly higher therapeutic 
margin than honokiol, with  coefficients being above 5. 
Biphenyl derivatives with lower IC50 values than honokiol for 
the HT-29 line, or else with higher -coefficients, were selected 
for the subsequent biological evaluations. The list included the 
following compounds: 3, 4, 5, 8, 9, 11, 14, 15, 16, 18, 20, 26, 28, 
30, 35, 37, 40, 44, 45, 46 and 47.  
 
 
 
 
 
 
  
Table 1. IC50 values (µg/mL) and selectivity coefficients for 
biphenyl derivatives 1-47.a 
Compound HEK-293 HT-29 MCF-7 b c 
Honokiol 9.3±1.6 6.1±0.5 5.0±0.7 1.5 1.9 
1 31.4±1.6 55±11 51±5 0.6 0.6 
2 52±3 51±12 1.6±0.2 1.0 33 
3 57±8 2.5±0.2 60±6 23 1.0 
4 54±6 2.7±1.1 >100 20 <0.5 
5 54.9±2.4 16±5 2.9±0.5 3.3 19 
6 54.1±1.8 44±8 56.0±1.6 1.2 1.0 
7 25±5 28.0±0.6 27.4±2.0 0.9 0.9 
8 5.5±1.3 1.1±0.5 47±3 5.1 0.1 
9 >100 5.2±0.2 >100 >19 1 
10 39±4 35±7 43±3 1.1 0.9 
11 50±8 22±4 44±5 2.3 1.1 
12 54±12 42±7 60±5 1.3 0.9 
13 47±5 49±5 28±7 1.0 1.7 
14 10.5±0.5 9.2±1.8 16±3 1.1 0.7 
15 68±11 2.5±1.2 51.6±0.4 28 1.3 
16 34±10 16.0±1.9 33±6 2 1.0 
17 50.1±1.6 54±6 99±8 0.9 0.5 
18 45±6 25±3 47±3 2 1.0 
19 17±6 45±8 >100 0.4 <0.2 
20 54±4 1.4±0.2 >100 38 >0.5 
21 44±8 47±8 42±5 0.9 1.0 
22 44±5 49±6 55±6 0.9 0.8 
23 >100 >100 1.4±0.2 1.0 >69 
24 31±8 27.3±0.4 52±4 1.2 0.6 
25 50±6 51±8 44.3±1.0 1.0 1.1 
26 31±6 3.4±1.2 >100 9.0 9 
27 14.6±2.4 72±8 48±5 0.2 0.3 
28 35±10 24±6 41±4 1.5 0.9 
29 55±7 49.3±0.2 >100 1.1 <0.6 
30 >100 5.4±1.4 6.5±0.6 >18 >15 
31 5.1±2.2 13.9±2.3 17.8±0.2 0.4 0.3 
32 2.0±0.7 >100 53±5 <0.02 0.04 
33 62±11 56±4 49.9±0.8 1.1 1.2 
34 27±3 55.2±1.6 >100 0.5 <0.3 
35 >100 33.7±1.5 >100 >3 1 
36 28±5 54±7 50.2±1.6 0.5 0.6 
37 >100 21±4 47±5 >5 >2 
38 >100 56±4 56±4 >2 >2 
39 29.2±1.4 49±4 >100 0.6 <0.3 
40 22±5 2.2±0.2 >100 10 <0.2 
41 26±8 41±3 45±10 0.6 0.6 
42 23±10 >100 55±5 <0.2 0.4 
43 23.1±0.6 29±8 48±3 0.8 0.5 
44 >100 26±8 34±9 >4 >3 
45 49.9±1.2 15±5 18±9 3.3 3 
46 20±3 4.0±1.6 >100 5 <0.2 
47 23±4 2.0±0.7 5.5±0.8 12.0 4 
a IC50 values are expressed as the compound concentration (µg/mL) that 
causes 50% inhibition of cell growth. The values are the average ( s.d.) of 
three different measurements performed as described in the Material and 
Methods section. b = IC50 (HEK-293) / IC50 (HT-29). c = IC50 (HEK-293) / 
IC50 (MCF-7). Values of  and  have been rounded off to a decimal figure. 
 
3.2. Effect of biphenyl derivatives on VEGFA protein secretion 
and VEGF gene inhibition on HT-29 cell line 
The influence of biphenyl derivatives on the expression and 
secretion of the VEGFA protein was performed on the HT-29 
cell line. Twenty-one selected biphenyl derivatives were tested at 
concentrations that were close to the IC50 values on this cell line 
(see Table 2). As compound 8 exhibited no activity at a 
concentration below its IC50 (1.1 g/mL) it was tested at 5 g/mL 
On the contrary, as compound 14 was very active, we deemed 
more appropriate to conduct the tests at the same concentration as 
in most of the other compounds. All the results were normalized 
according to the number of living cells. 
Table 2. Concentrations for testing selected compound. 
Concentration Biphenyl Derivatives 
3 g/mL 3, 4, 9, 14, 15, 20, 26, 30, 40, 46, 47 
5 g/mL Honokiol, 8 
10 g/mL 16 
15 g/mL 5, 11, 28, 37, 45 
20 g/mL 18, 44 
30 g/mL 35 
 
The amount of VEGFA protein was first determined by means 
of the ELISA procedure31 as described in the Material and 
Methods Section. Figure 3 shows the percentage of VEGFA 
secreted to the culture medium after 72 h of incubation in the 
presence of each of the selected compounds at the concentrations 
showed in Table 2. The value observed when cells were treated 
only with DMSO were used as the control value (standardized to 
100%). 
About one half of the studied derivatives showed an ability to 
downregulate the secretion of VEGFA protein higher than that 
exhibited by honokiol. Most particularly, compounds 4, 11, 16 
and 35 were able to inhibit the VEGFA protein secretion to about 
30% of the control value. All these four most active derivatives 
exhibited one hydroxyl and, at least, one methoxyl group in 
different rings. Besides, the preferred substitution patterns were 
ortho-ortho, meta-meta or ortho-meta (see Figure 5). 
In order to find out whether the selected biphenyl derivatives 
were able to downregulate the secretion of VEGFA protein by 
means of interference at the transcriptional level, we tested the 
ability of our compounds to inhibit the expression of the VEGFA 
gene. In this case, HT-29 cells were incubated for 48 h with the 
selected derivatives at the concentrations showed in Table 2, as 
well as with DMSO as the control test. The real time quantitative 
PCR (RT-qPCR) methodology32 was then used as described in 
the Material and Methods Section to determine the percentage of 
VEGFA gene expression related to control test (see Figure 4). 
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Figure 3. VEGFA protein secretion from HT-29 cells as determined by means of the ELISA procedure. At least three measurements were performed in each 
case. Bars represent mean values of VEGFA secretion (percentage values related to control) and error bars indicate standard errors of the mean. The statistical 
analysis was evaluated using one-way ANOVA with Dunnett's Multiple Comparison Test (P < 0.001) 
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Figure 4. Expression percentage of the VEGFA gene after 48 h of incubation of HT-29 cells determined by means of the RT-qPCR methodology. At least three 
measurements were performed in each case. Error bars indicate standard errors of the mean. The statistical analysis was evaluated using one-way ANOVA with 
Dunnett's Multiple Comparison Test (P < 0.001). 
 
Compounds 3, 4, 9, 15, 16, 20 and 26 were more effective 
than honokiol in inhibiting the expression of the VEGFA gene. 
These compounds were able to decrease the VEGFA gene 
expression to about 20% or less of the control value (DMSO). 
The most active derivative was 15, which inhibited gene 
expression to 5% of the control value. 
Figure 5 depicts the structures of the compounds showing the 
highest ability to inhibit (a) VEGFA secretion, and (b) VEGFA 
gene expression. Compounds 4 and 16 are able to cause strong 
inhibition of both protein secretion and gene expression (to about 
30% and 20% of the control, respectively). We can observe that 
the most active structures in inhibiting VEGFA protein secretion 
display one hydroxyl and at least one methoxyl group in different 
rings, whereas the most active ones in inhibiting VEGFA gene 
expression contain one hydroxyl group in each aromatic ring. 
The results discussed above do not show a good correlation 
between the VEGFA protein amount excreted to the medium and 
the degree of VEGFA gene expression. This suggests that these 
compounds possibly exert the control of VEGFA protein 
production at a phase different from that of gene transcription.33 
 
Figure 5. (a) Most active biphenyl derivatives in inhibiting VEGFA protein 
secretion from HT-29 cell line; (b) Most active biphenyl derivatives in 
inhibiting VEGFA gene expression from HT-29 cell line. 
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Figure 6. Expression percentage of the hTERT gene after 48 h of incubation as determined by means of the RT-qPCR methodology. At least three measurements 
were performed in each case. Error bars indicate standard errors of the mean. The statistical analysis was evaluated using one-way ANOVA with Dunnett's 
Multiple Comparison Test (P < 0.001). 
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Figure 7. Expression percentage of the c-Myc gene after 48 h of incubation as determined by means of the RT-qPCR methodology. At least three measurements 
were performed in each case. Error bars indicate standard errors of the mean. The statistical analysis was evaluated using one-way ANOVA with Dunnett's 
Multiple Comparison Test (P < 0.001). 
 
 
3.3. Effect of biphenyl derivatives on the inhibition of the hTERT 
and c-Myc genes  
In order to determine whether the studied compounds were 
able to downregulate the expression of the hTERT and c-Myc 
genes, we have performed an RT-qPCR analysis on HT-29 
tumoral cells. The cells were incubated for 48 h in the presence 
of DMSO (control) and in the presence of the selected 
compounds (see Table 2). Figures 6 and 7 show the results 
obtained, for the expression of the hTERT and c-Myc genes, 
respectively.  
Biphenyl derivatives 3, 4, 9, 15, 20, 26, 28, 35, 40 and 44 
were more active than honokiol in inhibiting hTERT gene 
expression. The most active compounds were 3, 4 and 20, which 
decreased the expression of the gene to 3%, 3% and 11%, 
respectively, of the control value. 
As regards the downregulation of the expression of the c-Myc 
gene (Figure 7), compounds 3, 4, 14, 15, 20, 26, 28, 30, 40 and 
46 turned out to be more active than honokiol. Here, compounds 
3, 4, 15 and 20 were able to inhibit c-Myc gene expression to less 
than 20% of control value. Moreover, compounds 4 and 20 were 
again very active, with gene expression reduced to 6 % and 11 % 
of the control, respectively. 
Figure 8(a) shows the structures of compounds that are able to 
inhibit simultaneously the expressions of both hTERT and c-Myc 
genes. These structures display one hydroxyl group in each 
aromatic ring or else one hydroxyl and one methoxyl group in 
different rings. The preferred substitution patterns are ortho-
ortho, meta-meta, ortho-para and meta-para. 
Figure 8(b) and 8(c) show the structures of the compounds 
that are able to inhibit either the hTERT or the c-Myc gen 
expressions, respectively. It is worth noting that the presence of 
an amine group gives rise to an increase of the inhibitory activity 
on the c-Myc gene. 
3.4. Conclusions 
We have synthetized forty-seven biphenyl derivatives related 
to honokiol. The cytotoxicity of the synthetic compounds was 
tested on HT-29, MCF-7 and HEK-293 cell lines. Although IC50 
values of these derivatives were in the low-medium micromolar 
range, twenty-one of them exhibited higher therapeutic margin 
than honokiol (see table 1). Table 3 summarizes the results 
observed for the five most active compounds in all the tested 
biological properties. Interestingly, these SAR studies showed 
that all most active biphenyl derivatives exhibit only two 
oxygenated functions, either two hydroxyls or one hydroxyl and 
one methoxyl, placed in different aromatic rings. Neither allyl or 
allyloxy nor amine groups improved the activity of the 
derivatives (see figure 9). Moreover the preferred substitution 
patterns for these both oxygenated groups are ortho- ortho and 
ortho-para. That would be due to the fact that these compounds 
are more rigid and could be blocked in the most active 
conformation to join their targets. It is very interesting to point 
out that these preferred substitution pattern in the biphenyl unit is 
the same as it is found in natural products honokiol (ortho-para) 
and magnolol (ortho- ortho).  
 
 
  
It is worth mentioning that compound 4 is the most promising 
as a multiple-gene targeting therapeutic agent because it is able to 
simultaneously block VEGF secretion and inhibit VEGF, hTERT 
and c-Myc gene expressions. Moreover, compound 4 works 
efficiently at a concentration in the low micromolar range and 
exhibits a good therapeutic margin. 
 
 
Figure 8. (a) Most active biphenyl derivatives in simultaneously inhibiting 
hTERT and c-Myc gene expressions from HT-29 cell line; (b) Most active 
biphenyl derivatives in inhibiting hTERT gene expression from HT-29 cell 
line; (b) Most active biphenyl derivatives in inhibiting c-Myc gene expression 
from HT-29 cell line. 
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Figure 9. SAR studies for dual activity on biphenyl derivatives 
Table 3. Honokiol and biphenyl derivatives with the highest 
activity in simultaneously inhibiting the expression of the 
VEGFA, hTERT and c-Myc genes. 
    % gene expression 
Comp. IC50a b % VEGFA secretion VEGFA  hTERT  c-Myc  
HKL 6.1 1.5 55 36 45 45 
3 2.5 23 57 23 3 18 
4 2.7 20 33 17 3 6 
15 2.5 28 50 5 29 16 
20 1.4 38 62 16 11 11 
26 3.4 9 52 35 30 39 
a IC50 values on HT-29 (µg/mL). b  = IC50 (HEK-293) / IC50 (HT-29) 
 
4. Materials and Methods 
4.1. Chemistry: general procedures 
General features. The signals of the deuterated solvent 
(CDCl3 or CD3OD) were taken as the reference. Multiplicity 
assignments of 13C signals were made by means of the DEPT 
pulse sequence. High resolution mass spectra were run by the 
electrospray mode (ESMS). IR data were measured with oily 
films on NaCl plates (oils) or KBr pellets (solids) and are given 
only for molecules with relevant functional groups (OH, C=O, 
NH2). Melting points are not corrected. Experiments which 
required an inert atmosphere were carried out under dry N2 in a 
flame-dried glassware. Commercially available reagents were 
used as received. Acronyms have been defined in Scheme 1. 
 
4.2. Reaction conditions 
General Method A28 
A mixture of the appropriate brominated arene (1 mmol), the 
required boronic acid (1.3 mmol) and PdCl2(dppf)·CH2Cl2 
complex (0.04 g, ca. 0.05 mmol) were dissolved under an inert 
atmosphere in DME (7 mL). A 2M Na2CO3 solution (3 mL) was 
then added, and the mixture was stirred at reflux until 
consumption of the starting materials (ca. 15-18 h, TLC 
monitoring). The mixture was poured into a separation funnel, 
diluted with water and extracted with ethyl ether (4 x 10 mL). 
The combined organic layers were washed with brine. After 
desiccation over anhydrous Na2SO4, the volatiles were removed 
under reduced pressure. This afforded an oily material which was 
subjected to column chromatography on silica gel (hexane-
EtOAc mixtures) to yield the desired biphenyl derivative. 
 
General Method B30 
The appropriate brominated arene (1 mmol) was placed in a 
10-mL glass tube together with the corresponding boronic acid 
(1.3 mmol), Pd(OAc)2 (0.001 g, ca. 0.005 mmol) and Na2CO3 
(414 mg, 4 mmol) and a 1:1 ethanol/water mixture (2 mL). The 
mixture was stirred until homogeneity and the vessel was sealed 
with a septum, shaken, and placed into the microwave cavity. 
Microwave irradiation was initiated with a potency of 210 W, the 
temperature being then increased from room temperature to 150 
ºC. Once this value was reached, the reaction mixture was held at 
this temperature for 1 h. After allowing the mixture to cool down 
to room temperature, the reaction vessel was opened and the 
mixture was poured into a separation funnel, diluted with water 
and extracted with ethyl ether (4 x 10 mL). The combined 
organic layers were washed with brine. After desiccation over 
anhydrous Na2SO4, the volatiles were removed under reduced 
pressure. This afforded an oily material which was subjected to 
column chromatography on silica gel (hexane-EtOAc mixtures) 
to yield the desired biphenyl derivative. 
 
General Method C29 
A mixture of the appropriate brominated arene (1 mmol), the 
required boronic acid (1.3 mmol), Pd(OAc)2 (0.001 g, ca. 0.005 
mmol) and Na2CO3 (414 mg, 4 mmol) was dissolved in a 1:1 
ethanol/water mixture (3 mL). The mixture was then stirred at 70 
ºC until consumption of the starting materials (ca. 4 h, TLC 
monitoring). The mixture was poured into a separation funnel, 
diluted with water and extracted with ethyl ether (4 x 10 mL). 
The combined organic layers were washed with brine. After 
desiccation over anhydrous Na2SO4, the volatiles were removed 
  
under reduced pressure. This afforded an oily material which was 
subjected to column chromatography on silica gel (hexane-
EtOAc mixtures) to yield the desired biphenyl derivative. 
General Method D29 
A mixture of the appropriate brominated arene (1 mmol), the 
required boronic acid (1.5 mmol), Pd(OAc)2 (1 mg, ca. 0.005 
mmol) and Na2CO3 (212 mg, 2 mmol) was dissolved in a 1:1 
acetone/water mixture (7 mL). The mixture was then stirred at 35 
ºC until consumption of the starting materials (ca. 1 h, TLC 
monitoring). The mixture was poured into a separation funnel, 
diluted with water and extracted with ethyl ether (4 x 10 mL). 
The combined organic layers were washed with brine. After 
desiccation over anhydrous Na2SO4, the volatiles were removed 
under reduced pressure. This afforded an oily material which was 
subjected to column chromatography on silica gel (hexane-
EtOAc mixtures) to yield the desired biphenyl derivative. 
Yields and physical data are given in the Supplementary Data. 
 
4.3. Biological procedures 
4.3.1. Reagents and cell culture 
Cell culture media were purchased from Gibco (Grand Island, 
NY, USA). Fetal bovine serum (FBS) was a product of Harlan-
Seralab (Belton, U.K.). Supplements and other chemicals not 
listed in this section were obtained from Sigma Chemicals Co. 
(St. Louis, Mo., USA). Plastics for cell culture were supplied by 
Thermo ScientificTM BioLite. All tested compounds were 
dissolved in DMSO at a concentration of 10 mg/mL and stored at 
–20C until use. 
Cell lines were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) containing glucose (1 g/L), glutamine (2 mM), 
penicillin (50 IU/mL), streptomycin (50 µg/mL) and 
amphoterycin (1.25 µg/mL), supplemented with 10% FBS. 
4.3.2. Cytotoxicity assays 
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT; Sigma Chemical Co., St. Louis, MO) dye 
reduction assay in 96-well microplates was used, as previously 
described.34 Some 5 x 103 cells of HT-29, MCF-7 or HEK-293 
cells in a total volume of 100 µL of their respective growth media 
were incubated with serial dilutions of the tested compounds. 
After 3 days of incubation (37 C, 5% CO2 in a humid 
atmosphere), 10 µl of MTT (5 mg/mL in PBS) were added to 
each well and the plate was incubated for further 4 h (37 C). The 
resulting formazan was dissolved in 150 µL of 0.04 N HCl/2-
propanol and read at 550 nm. All determinations were carried out 
in triplicate. 
4.3.3. ELISA analysis 
HT-29 cells at 70–80% confluence were collected after serum 
starvation for 24 h. Cells were incubated at the concentrations 
showed in Table 2 of the corresponding drugs in DMSO for 72 h 
(Fig. 3). Culture supernatants were collected and VEGFA protein 
secreted by HT-29 cells was determined using Invitrogen Human 
Vascular Endothelial Growth Factor ELISA Kit according to the 
manufacturer’s instructions. 
4.3.4. RT-qPCR analysis 
HT-29 cells at 70–80% confluence were collected after serum 
starvation for 24 h. Cells were incubated at the concentrations 
showed in Table 2 of the corresponding drugs in DMSO for 48 h. 
Cells were collected and the total cellular RNA from HT-29 cells 
was isolated using Ambion RNA extraction Kit according to the 
manufacturer’s instructions. The cDNA was synthesized by 
MMLV-RT with 1-21 g of extracted RNA and oligo(dT)15 
according to the manufacturer’s instructions. 
Amplification of the genes was performed by use of a 
StepOnePlus™ thermalcycler. Fast TaqMan Gene Expression 
Master Mix containing the appropriate buffer for the 
amplification conditions, dNTPs, thermostable DNA polymerase 
enzyme and a passive reference probe was used. Each of the 
genes were amplified using predesigned primers by Life 
Technologies TaqMan® Gene Expression Assays, Hs99999903-
m1 (-actin), Hs00900055-m1 (VEGF), Hs00972646-m1 
(hTERT) and Hs00153408-m1 (c-Myc). 
 
 
 
4.3.5. Statistical analysis 
Data are expressed as the mean ± SEM. Statistical analyses 
were done using Microsoft Excel and GraphPad Prism®. 
Differences between means were determined using one-way 
ANOVA with Dunnett's Multiple Comparison Test, and 
considered to be statistically significant at ≤0.05. 
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